103
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy

ORCID Icon, , ORCID Icon, , , ORCID Icon, ORCID Icon & show all
Pages 3149-3155 | Published online: 10 Sep 2020

References

  • Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE Global estimates of diabetes prevalence for 2013 and projections for 2035. Diab Res Clin Pract. 2014;103(2):137–149. doi:10.1016/j.diabres.2013.11.002
  • International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Bruxelas, Bélgica: International Diabetes Federation; 2015. doi:https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/13-diabetes-atlas-seventh-edition.html.
  • Cho NH, Shaw JE, Karuranga S, et al.. Global estimates of diabetes prevalence for 2017 and projections for 2045. Diab Res Clin Pract. 2018;138:271–281. doi:10.1016/j.diabres.2018.02.023.
  • Dodda D, Ciddi V. Plants used in the management of diabetic complications. Indian J Pharm Sci. 2014;76(2):97–106.
  • Frank RN. Diabetic retinopathy and systemic factors. Middle East Afr J Ophthalmol. 2015;22(2):151–156. doi:10.4103/0974-9233.154388
  • Mitchell P, Wong TY. Diabetic macular edema treatment guideline working group. Management paradigms for diabetic macular edema. Am J Ophthalmol. 2014;157(3):e1–8. doi:10.1016/j.ajo.2013.11.012
  • Stewart MW, Flynn HW, Schwartz SG, Scott IU. Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects. Expert Opin Drug Deliv. 2016;13(9):1277–1287. doi:10.1080/17425247.2016.1198771
  • Kumar B, Gupta SK, Saxena R, Srivastava S. Current trends in the pharmacotherapy of diabetic retinopathy. J Postgrad Med. 2012;58(2):132–139. doi:10.4103/0022-3859.97176
  • Lu L, Jiang Y, Jaganathan R, Hao Y Current advances in pharmacotherapy and technology for diabetic retinopathy: a systematic review. J Ophthalmol. 2018 17;2018:1694187.
  • Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222. doi:10.1159/000458539
  • Blinder KJ, Dugel PU, Chen S, et al. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO study report 1). Clin Ophthalmol. 2017;11:393–401. doi:10.2147/OPTH.S128509
  • Bahrami B, Hong T, Zhu M, Schlub TE, Chang A. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2017;255(6):1133–1140. doi:10.1007/s00417-017-3624-y
  • Klein R, Klein BE, Moss SE, Cruickshanks KJ The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105(10):1801–1815. doi:10.1016/S0161-6420(98)91020-X
  • Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina. 2004;24(5 Suppl):S3–19. doi:10.1097/00006982-200410001-00002
  • Lv J, Chen MM, Mu ZH, et al. Intravitreal bevacizumab injection attenuates diabetic retinopathy in adult rats with experimentally induced diabetes in the early stage. J Diab Res. 2018;9(2018):9216791.
  • Zhao Y, Singh RP The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. Drugs Context 2018; 13(7):212532.
  • Matsuda S, Tam T, Singh RP, et al. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. J Diab Complications. 2014;28(2):166–170. doi:10.1016/j.jdiacomp.2013.11.009
  • Motta AAL, Bonanomi MTBC, Ferraz DA, et al. Short-term effects of intravitreal bevacizumab in contrast sensitivity of patients with diabetic macular edema and optimizing glycemic control. Diab Res Clin Pract. 2019;149:170–178. doi:10.1016/j.diabres.2019.02.002
  • PARECER TÉCNICO Nº 51/GEAS/GGRAS/DIPRO/2018. Available from: http://www.ans.gov.br/images/stories/parecer_tecnico/uploads/parecer_tecnico/_PARECER%20TCNICO%20N%2051-2018_TRATAMENTO%20OCULAR%20QUIMIOTERAPICO%20COM%20ANTIANGIOGENICO_VERSO%20FINAL_28122017%20verso%202%201%2031012018.pdf. Accessed November 11, 2018.